Participant flow

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma · Source last updated 2023-06-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   * A treatment cycle is defined as 28 consecutive days. * Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months. Nivolumab: Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and Lenalidomide: Oral, predetermined dosage, Days 1-21 of cycle 1-12 Dexamethasone: Oral, Days 1, 8, 15 of cycle 1-6

   id

   FG000

   title

   Nivolumab, Lenalidomide, Dexamethasone

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         8

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         8

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice